Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus

doi:10.12114/j.issn.1007-9572.2021.01.105

Abstract

Abstract: Type 2 diabetes mellitus（T2DM） is a progressive disease characterized by hyperglycemia，which is generally considered as a disease requiring chronic hypoglycaemic agents therapy. In recent years，a large number of research results have shown that lifestyle intervention，drug therapy，and metabolic surgery can promote the remission of T2DM combined with overweight and obesity，so that patients can avoid the use of hypoglycemic drugs for a long time. T2DM relief can help reduce the psychological burden of patients，enhance patients' confidence in complying with healthy lifestyles，and improve patients' quality of life. In the long term，it can also delay disease progression and reduce the risk of life-long complications. In order to help Chinese clinicians to standardize the clinical diagnosis and treatment related to the alleviation of T2DM in overweight and obese T2DM patients，promote the development of related research，and enable patients to obtain safe and effective intervention measures，the Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus was formulated.

Key words: Diabetes mellitus, type 2；Remission；Obesity；Critical pathways；Expert consensus

摘要： 2型糖尿病（T2DM）是一种以高血糖为特征的进展性疾病，一直被认为需要长期使用降糖药物治疗。近年来大量研究结果显示，通过生活方式干预、药物治疗以及代谢手术能够促进合并超重和肥胖的T2DM缓解，使患者在较长时间内免于使用降糖药物。T2DM缓解有助于减轻患者心理负担、增强患者依从健康生活方式的信心，提升患者生活质量，远期还可以延缓疾病进展速度，降低终生并发症的发生风险。为帮助我国临床医生规范开展在超重和肥胖T2DM患者中缓解T2DM相关的临床诊疗工作，促进相关研究的发展，使患者获得安全、有效的干预措施，特制定《缓解2型糖尿病中国专家共识》。

关键词: 糖尿病, 2型；缓解；肥胖症；临床路径；专家共识

Committee of Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus. Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus　[J]. Chinese General Practice, 2021, 24(32): 4037-4048. DOI: 10.12114/j.issn.1007-9572.2021.01.105.
《缓解2型糖尿病中国专家共识》编写专家委员会. 缓解2型糖尿病中国专家共识[J]. 中国全科医学, 2021, 24(32): 4037-4048. DOI: 10.12114/j.issn.1007-9572.2021.01.105.

References

［1］WANG L M，ZHOU B，ZHAO Z P，et al. Body-mass index and obesity in urban and rural China：findings from consecutive nationally representative surveys during 2004-18［J］. Lancet，2021，398（10294）：53-63. DOI：10.1016/S0140-6736（21）00798-4.
［2］COLDITZ G A，WILLETT W C，ROTNITZKY A，et al. Weight gain as a risk factor for clinical diabetes mellitus in women［J］. Ann Intern Med，1995，122（7）：481-486.
［3］HOU X H，LU J M，WENG J P，et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults：a national diabetes and metabolic disorders survey［J］. PLoS One，2013，8（3）：e57319. DOI：10.1371/journal.pone.0057319.
［4］YANG W，LU J，WENG J，et al. Prevalence of diabetes among men and women in China［J］. N Engl J Med，2010，362（12）：1090-1101. DOI：10.1056/nejmoa0908292.
［5］LI Y Z，TENG D，SHI X G，et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association：national cross sectional study［J］. BMJ，2020，369：m997. DOI：10.1136/bmj.m997.
［6］GONG Q H，ZHANG P，WANG J P，et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance：30-year results of the Da Qing Diabetes Prevention Outcome Study［J］. Lancet Diabetes Endocrinol，2019，7（6）：452-461.
［7］PAN X R，LI G W，HU Y H，et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study［J］. Diabetes Care，1997，20（4）：537-544. DOI：10.2337/diacare.20.4.537.
［8］PAN X R，HU Y H，LI G W，et al. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study［J］. Diabetes Care，1993，16（1）：150-156.
［9］KNOWLER W C，BARRETT-CONNOR E，FOWLER S E，et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin［J］. N Engl J Med，2002，346（6）：393-403.
［10］LINDSTR?M J，LOUHERANTA A，MANNELIN M，et al. The Finnish Diabetes Prevention Study（DPS）：lifestyle intervention and 3-year results on diet and physical activity［J］. Diabetes Care，2003，26（12）：3230-3236. DOI：10.2337/diacare.26.12.3230.
［11］LEAN M E，LESLIE W S，BARNES A C，et al. Primary care-led weight management for remission of type 2 diabetes（DiRECT）：an open-label，cluster-randomised trial［J］. Lancet，2018，391（10120）：541-551. DOI：10.1016/S0140-6736（17）33102-1.
［12］Look AHEAD Research Group，WING R R，BOLIN P，et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes［J］. N Engl J Med，2013，369（2）：145-154.
［13］KRAMER C K，ZINMAN B，CHOI H，et al. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes［J］. BMJ Open Diabetes Res Care，2016，4（1）：e000270. DOI：10.1136/bmjdrc-2016-000270.
［14］PARK S，CHOI S B. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy［J］. Diabetes Metab Res Rev，2003，19（2）：124-130. DOI：10.1002/dmrr.343.
［15］LI Y B，XU W，LIAO Z H，et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function［J］. Diabetes Care，2004，27（11）：2597-2602. DOI：10.2337/diacare.27.11.2597.
［16］WENG J P，LI Y B，XU W，et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes：a multicentre randomised parallel-group trial［J］. Lancet，2008，371（9626）：1753-1760. DOI：10.1016/S0140-6736（08）60762-X.
［17］KRAMER C K，ZINMAN B，RETNAKARAN R. Short-term intensive insulin therapy in type 2 diabetes mellitus：a systematic review and meta-analysis［J］. Lancet Diabetes Endocrinol，2013，1（1）：28-34. DOI：10.1016/S2213-8587（13）70006-8.
［18］World Health Organization. Global report on diabetes［EB/OL］. （2016-04-21）［2021-05-10］. http://www.who.int/diabetes/global-report/en/.
［19］RIDDLE M C，CEFALU W T，EVANS P H，et al. Consensus report：definition and interpretation of remission in type 2 diabetes［J］. Diabetologia，2021. DOI：10.1007/S00125-021-05542-Z.
［20］CINTI F，BOUCHI R，KIM-MULLER J Y，et al. Evidence of β-cell dedifferentiation in human type 2 diabetes［J］. J Clin Endocrinol Metab，2016，101（3）：1044-1054. DOI：10.1210/jc.2015-2860.
［21］TALCHAI C，XUAN S H，LIN H V，et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure［J］. Cell，2012，150（6）：1223-1234. DOI：10.1016/j.cell.2012.07.029.
［22］RUBINO F，COHEN R V. Effect of diet versus gastric bypass on metabolic function in diabetes［J］. N Engl J Med，2020，383（24）：2390-2391. DOI：10.1056/NEJMc2030030.
［23］KARTER A J，NUNDY S，PARKER M M，et al. Incidence of remission in adults with type 2 diabetes：the diabetes & aging study［J］. Diabetes Care，2014，37（12）：3188-3195. DOI：10.2337/dc14-0874.
［24］GOLDENBERG J Z，DAY A，BRINKWORTH G D，et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission：systematic review and meta-analysis of published and unpublished randomized trial data［J］. BMJ，2021，372：m4743. DOI：10.1136/bmj.m4743.
［25］STEVEN S，HOLLINGSWORTH KG，AL-MRABEH A，et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes：pathophysiological changes in responders and nonresponders［J］.Diabetes Care，2016，39（5）：808-815. DOI：10.2337/dc15-1942.
［26］DAMBHA-MILLER H，DAY A J，STRELITZ J，et al. Behaviour change，weight loss and remission of type 2 diabetes：a community-based prospective cohort study［J］. Diabet Med，2020，37（4）：681-688. DOI：10.1111/dme.14122.
［27］SARATHI V，KOLLY A，CHAITHANYA H B，et al. High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy［J］. J Nat Sci Biol Med，2017，8（1）：60-63. DOI：10.4103/0976-9668.198343.
［28］NIEUWOUDT S，FEALY C E，FOUCHER J A，et al. Functional high-intensity training improves pancreatic β-cell function in adults with type 2 diabetes［J］. Am J Physiol Endocrinol Metab，2017，313（3）：E314-320. DOI：10.1152/ajpendo.00407.2016.
［29］PRICE S，LE Q N，WHITEN D. Lifestyle and pharmacotherapy for weight loss in preventing or delaying diabetes［J］. Am J Lifestyle Med，2017，12（1）：34-37. DOI：10.1177/1559827617740825.
［30］史轶蘩，邓洁英，朱文玲，等. 奥利司他对中国肥胖患者的疗效和安全性分析［J］.中华内分泌代谢杂志，2001，17（6）：383-387. DOI：10.3760/j.issn:1000-6699.2001.06.022.
［31］CAI X L，JI L W，CHEN Y F，et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients：a meta-analysis［J］. J Diabetes Investig，2017，8（4）：510-517. DOI：10.1111/jdi.12625.
［32］FRíAS J P，GUJA C，HARDY E，et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy（DURATION-8）：a 28 week，multicentre，double-blind，phase 3，randomised controlled trial［J］. Lancet Diabetes Endocrinol，2016，4（12）：1004-1016. DOI：10.1016/S2213-8587（16）30267-4.
［33］GUJA C，FRíAS J P，SOMOGYI A，et al. Effect of exenatide QW or placebo，both added to titrated insulin glargine，in uncontrolled type 2 diabetes：the DURATION-7 randomized study［J］. Diabetes Obes Metab，2018，20（7）：1602-1614.
［34］RUBINO D，ABRAHAMSSON N，DAVIES M，et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity：the STEP 4 randomized clinical trial［J］. JAMA，2021，325（14）：1414-1425. DOI：10.1001/jama.2021.3224.
［35］JI L N，DONG X L，LI Y M，et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China：a 30-week，double-blind，phase 3a，randomized trial［J］. Diabetes Obes Metab，2021，23（2）：404-414.
［36］KESSING L V，RYTGAARD H C，EKSTR?M C T，et al. Antidiabetes agents and incident depression：a nationwide population-based study［J］. Diabetes Care，2020，43（12）：3050-3060. DOI：10.2337/dc20-1561.
［37］ABDUL-GHANI M A，PUCKETT C，TRIPLITT C，et al. Initial combination therapy with metformin，pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes（EDICT）：a randomized trial［J］. Diabetes Obes Metab，2015，17（3）：268-275. DOI：10.1111/dom.12417.
［38］Summary of revisions：standards of medica1 care in diabetes-2020［J］. Diabetes Care，2020，43（Suppl 1）：S4-6. DOI：10.2337/dc20-Srev.
［39］RETNAKARAN R，EMERY A，YE C，et al. Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes（RESET-IT Main）：a 2-year randomized controlled trial［J］. Diabetes Obes Metab，2021，23（8）：1926-1935. DOI：10.1111/dom.14421.
［40］SCHAUER P R，BHATT D L，KIRWAN J P，et al. Bariatric surgery versus intensive medical therapy for diabetes——3-year outcomes［J］. N Engl J Med，2014，370（21）：2002-2013.
［41］SJ?STR?M L，PELTONEN M，JACOBSON P，et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications［J］. JAMA，2014，311（22）：2297-2304. DOI：10.1001/jama.2014.5988.
［42］MINGRONE G，PANUNZI S，DE GAETANO A，et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes：10-year follow-up of an open-label，single-centre，randomised controlled trial［J］. Lancet，2021，397（10271）：293-304. DOI：10.1016/S0140-6736（20）32649-0.
［43］COURCOULAS A P，BELLE S H，NEIBERG R H，et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment：a randomized clinical trial［J］. JAMA Surg，2015，150（10）：931-940.
［44］中国超重肥胖医学营养治疗专家共识编写委员会.中国超重/肥胖医学营养治疗专家共识（2016年版）［J］. 中华糖尿病杂志，2016，8（9）：525-540. DOI：10.3760/cma.j.issn.1674-5809.2016.09.004.
［45］American Diabetes Association. 7.Obesity Management for the Treatment of Type 2 Diabetes［J］. Diabetes Care，2017，40（Suppl 1）：S57-63. DOI: 10.2337/dc17-S010.
［46］王勇，王存川，朱晒红，等. 中国肥胖及2型糖尿病外科治疗指南（2019版）［J］. 中国实用外科杂志，2019，39（4）：301-306. DOI：10.19538/j.cjps.issn1005-2208.2019.04.01.
［47］Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up：the Diabetes Prevention Program Outcomes Study［J］. Lancet Diabetes Endocrinol，2015，3（11）：866–875. DOI：10.1016/s2213-8587（15）00291-0.
［48］SJ?STR?M L，LINDROOS A K，PELTONEN M，et al. Lifestyle，diabetes，and cardiovascular risk factors 10 years after bariatric surgery［J］. N Engl J Med，2004，351（26）：2683-2693.
［49］RAWSHANI A，RAWSHANI A，FRANZéN S，et al. Risk factors，mortality，and cardiovascular outcomes in patients with type 2 diabetes［J］. N Engl J Med，2018，379（7）：633-644. DOI：10.1056/NEJMoa1800256.
［50］ADAMS T D，DAVIDSON L E，LITWIN S E，et al. Weight and metabolic outcomes 12 years after gastric bypass［J］. N Engl J Med，2017，377（12）：1143-1155. DOI：10.1056/NEJMoa1700459.

[1]	WANG Yang, ZHAO Shiting, CHEN Yingying, SUN Zilin, QIU Shanhu. Key Points of Exercise Intervention and Implementation for People with Complications of Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(21): 2989-2994.
[2]	LI Jiawei, GAO Xinyi, GE Aoqi, LI Juanjuan, YUAN Beibei. Demand and Associated Factors for Integrated Medical Care and Preventive Services among Patients with Type 2 Diabetes [J]. Chinese General Practice, 2026, 29(21): 3028-3039.
[3]	PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988.
[4]	AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003.
[5]	GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859.
[6]	ZHANG Xiaojuan, LIU Yang, PENG Bo, YE Yuan, ZHU Kun. Study on the Prevention and Treatment of Hypertension and Diabetes Mellitus in Community Hospital [J]. Chinese General Practice, 2026, 29(19): 2614-2620.
[7]	JIAN Yingchun, ZENG Yongqin, ZHANG Haiping, WANG Zhengdi, AN Ke, YAN Rui. Recent Advances in Mitochondrial Dysfunction in Chronic Metabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2577-2584.
[8]	LI Yachan, YANG Yang, XU Qianting, KE Tingyu. Association between the Chinese Visceral Adiposity Index and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(18): 2482-2488.
[9]	LI Menglin, DING Fang, QIAN Yu, PU Dong, DU Qianqian, GUAN Tianhang, HE Yilin. Study on Glycemic Control Status and Influencing Factors among Community Diabetic Patients [J]. Chinese General Practice, 2026, 29(17): 2334-2339.
[10]	WANG Rui, LUO Dan, YANG Cuicui, WENG Xinyi, WANG Yubing, XU Jingjing. Complex Network Analysis of Resilience in Adolescents with Type 1 Diabetes Mellitus Based on Multi-sourced Stigma [J]. Chinese General Practice, 2026, 29(16): 2264-2272.
[11]	FU Mingyuan, YU Xiaoyi, GE Caiying, KONG Min. Impaired Awareness of Hypoglycemia: Prevalence and Determinants among Community-based Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(16): 2252-2258.
[12]	JIN Chunhua, ZHANG Yawen, LI Lianxi. Association between Serum Bilirubin Within the Normal Range and Carotid Plaques in Elderly Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(15): 1986-1991.
[13]	YU Jie, WU Chunxiang, CAI Ning, ZHU Xiaoxia, SHEN Li. Study on Multidimensional Healthcare-seeking Behavior Patterns and Influencing Factors in Diabetic Patients [J]. Chinese General Practice, 2026, 29(14): 1827-1839.
[14]	YAN Beibei, XU Huaifu. Children's Type 1 Diabetes-specific Self-reported Outcomes Scales: Measurement Properties Evaluation Based on COSMIN Guidelines [J]. Chinese General Practice, 2026, 29(12): 1624-1632.
[15]	YANG Rong, JIN Hua, SHI Ling, YI Chuntao, HOU Jin, CHEN Chen, HUAN Hongmei, NI Hengru, YU Dehua. A Survey on the Quality of Diabetes Normative Management at Grassroots Level [J]. Chinese General Practice, 2026, 29(12): 1541-1547.